• サイトマップ
• 求人情報
• アクセス
• お問い合わせ

更新日：2008年12月26日

1. 論文
   1. 委員会承認の治療研究

      JCOG8502

      M Fukuoka, K Furuse, N Saijo, et al.: Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer. J Natl Cancer Inst. 83(12): 855-861, 1991.

      JCOG8803

      Y Ariyoshi, M Fukuoka, K Furuse, et al.: Concurrent Cisplatin-Etoposide Chemotherapy plus Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer. Jpn J Clin Oncol. 24: 275-281, 1994.

      JCOG8809

      K Eguchi, H Etou, S Miyachi, et al.: A Study of Dose Escalation of Teniposide (VM-26) plus Cisplatin (CDDP) with Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) in Patients with Advanced Small Cell Lung Cancer. Eur J Cancer. 30A (2): 188-194, 1994.

      JCOG8902

      K Kubota, T Tamura, M Fukuoka, et al.: Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. Ann Oncol. 11: 445-450, 2000.

      JCOG9011

      H Ohmatsu, K Eguchi, T Shinkai, et al.: A Randomized Cross-Over Study of High-Dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High-dose Cisplatin. Jpn J Cancer Res. 85: 1151-1158, 1994.

      JCOG9104

      M Takada, M Fukuoka, M Kawahara, et al.: Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104 (JCOG9104). J Clin Oncol. 20: 3054-3060, 2002.

      JCOG9110

      T Shinkai, H Arioka, H Kunikane, et al.: Phase I Clinical Trial of Irinotecan (CPT-11), 　7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and Cisplatin in Combination with Fixed Dose of Vindesine in Advanced Non-Small Cell Lung Cancer. Cancer Res. 54: 2636-2642, 1994.

      JCOG9111

      H Asamoto, M Kawahara, F Iwami, et al.: Cisplatin plus Oral Etoposide in the Treatment of Patients with Advanced Small Cell Lung Cancer. Jpn J Clin Oncol. 28(12): 745-748, 1998.

      JCOG9202

      K Furuse, M Fukuoka, N Saijo et al.: Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol. 16(6): 2126-2132, 1998.

      JCOG9302

      F Oshita, K Noda, Y Nishiwaki, et al.: Phase II Study of Irinotecan and Etoposide in Patients with Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 15: 304-309, 1997.

      JCOG9405

      A Yokoyama, Y Kurita, N Saijo, et al.: Dose-Finding Study of Irinotecan and Cisplatin plus Concurrent Radiotherapy for Unresectable stage III Non-Small-Cell Lung Cancer. Br J Cancer. 78(2): 257-262, 1998.

      JCOG9406

      M Ando, K Eguchi, T Shinkai, et al.: Phase I Study of Sequentially Administered Topoisomerase I Inhibitor (Irinotecan) and Topoisomerase II Inhibitor (Etoposide) for Metastatic Non-Small-Cell Lung Cancer. Br J Cancer. 76(11): 1494-1499, 1997.

      JCOG9409

      H Okamoto, K Watanabe, Y Nishiwaki, et al.: Phase II Study of Area Under the Plasma-Concentration-Versus-Time Curve-Based Carboplatin Plus Standard-Dose Intravenous Etoposide in Elderly patients with Small-Cell Lung Cancer. J Clin Oncol. 17(11): 3540-3545, 1999.

      JCOG9413

      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis - JCOG study 9413. Br J Cancer. 76(1): 90-92, 1997.

      JCOG9507

      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG9507. Br J Cancer. 88: 808-813, 2003.

      JCOG9511

      N Noda, Y Nishiwaki, M Kawahara, et al.: Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. N Engl J Med. 346(2): 85-91, 2002.

      JCOG9515

      K Yoshida, T Sugiura, N Takifuji, et al.: Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer(JCOG9515). Lung Cancer 58: 362-368, 2007.

      JCOG9608

      F Oshita, K Yamada, Y Kato, et al.: Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Parmacol. 52: 73-78, 2003.

      JCOG9702

      H Okamoto, K Watanabe, H Kunikane, et al.: Randomized phase III trial of carboplatin plus etoposide vs. split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG9702. Br J Cancer. 97(2): 162-169, 2007.

      JCOG9807

      K Yamada, F Oshita, K Noda,et al.: Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology. 66: 94-100, 2004.

      JCOG9812

      S Atagi, M Kawahara, T Tamura, et al.: Standard Thoracic Radiotherapy With　or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol. 35(4):195-201, 2005.

      JCOG9902-DI

      I Sekine, Y Nishiwaki, K Noda, et al.: Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol. 14: 709-714, 2003.

      JCOG9903

      K Kubota, Y Nishiwaki, T Sugiura, et al.: Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res. 11(15): 5534-5538, 2005.

   2. グループ代表者管理の治療研究

      なし

   3. 附随研究等
      • M Kawahara, M Fukuoka, N Saijo, et al.: Prognostic Factors and Prognostic Staging System for Small Cell Lung Cancer. Jpn J Clin Oncol. 27 (3): 158-165, 1997.
      • Y Ohe, T Tamura, N Saijo,et al.: Lung-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci. 94: 729-734, 2003.
   4. 総説・解説

      なし

2. 主な学会発表
   1. 委員会承認の治療研究

      JCOG9104

      M Takada, M Fukuoka, K Furuse, et al.: Phase III Study of Concurrent versus Sequential Thoracic Radiotherapy in Combination with Cisplatin and Etoposide for Limited-Stage Small Cell Lung Cancer: Preliminary Results of the Japan Clinical Oncology Group. 32th Annual Meeting of the American Society of Clinical Oncology. May 1996. Proc Am Soc Clin Oncol. 15: 372, 1996.

      K Goto, Y Nishiwaki, M Takada, et al.: Final Results of a Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy (TRT) in Combination with Cisplatin (P) and Etoposide (E) for Limited-Stage Small Cell Lung Cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) Study. 35th Annual Meeting of the American Society of Clinical Oncology. May 1999. Proc Am Soc Clin Oncol. 18: 468a, 1999.

      JCOG9106

      K Furuse, K Kubota, Y Nishiwaki, et al.: Phase III Study of Dose-Intensive Weekly Chemotherapy with Recombinant Human Granulocyte-Colony-Stimulating Factor versus Standard Chemotherapy in Extensive Stage Small Cell Lung Cancer. 32th Annual Meeting of the American Society of Clinical Oncology. May 1996. Proc Am Soc Clin Oncol. 15: 375, 1996.

      JCOG9202

      K Furuse, M Fukuoka, Y Takada, et al.: A Randomized Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination with Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non-Small Cell Lung Cancer: Preliminary analysis. Abstract #1649: 33th Annual Meeting of the American Society of Clinical Oncology. May 1997. Proc Am Soc Clin Oncol. 16: 459a, 1997.

      JCOG9302

      K Goto, Y Nishiwaki, N Saijo, et al.: A Phase II Study of Irinotecan (CPT-11) and Etoposide (VP-16) for Metastatic Non-Small Cell Lung Cancer (NSCLC): Japan Clinical Oncology Group (JCOG) Trial. 31th Annual Meeting of the American Society of Clinical Oncology. May 1995. Proc Am Soc Clin Oncol. 14: 1995.

      JCOG9306

      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Long-term results of twice-daily high-dose thoracic radiotherapy (TRT) alternating with chemotherapy (CT) of cisplatin and vindesine for unresectable stage III non-small cell lung cancer (NSCLC). JCOG study 9306. 36th Annual Meeting of the American Society of Clinical Oncology. May 2000. Proc Am Soc Clin Oncol. 19: 509a, 2000.

      JCOG9406

      M Ando, K Eguchi, T Shinkai, et al.: Phase I Study of Sequentially Administered Irinotecan and Etoposide for Metastatic Non-Small Cell Lung Cancer. 32th Annual Meeting of the American Society of Clinical Oncology. May 1996. Proc Am Soc Clin Oncol. 15: 480, 1996.

      JCOG9409

      H Okamoto, K Watanabe, K Mori, et al.: A Phase II Study of Carboplatin (CBDCA) and Etoposide (ETP) in Elderly Patients with Small Cell Lung Cancer (SCLC): Japan Clinical Oncology Group (JCOG) Study 9409. 34th Annual Meeting of the American Society of Clinical Oncology. May 1998. Proc Am Soc Clin Oncol. 17: 473a, 1998.

      JCOG9504

      H Saka, K Shimokata, S Yoshida, et al.: Irinotecan and Concurrent Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study of Japan Clinical Oncology Group (JCOG9504). 33th Annual Meeting of the American Society of Clinical Oncology. May 1997. Proc Am Soc Clin Oncol. 16: 447a 1997.

      JCOG9507

      I Sekine, Y Nishiwaki, R Kakinuma, et al.: PhaseI/II Trial of Weekly Cisplatin (CDDP), Etoposide (ETOP) and Irinotecan (CPT) for Metastatic Lung Cancer (JCOG Study 9507). 34th Annual Meeting of the American Society of Clinical Oncology. May 1998. Proc Am Soc Clin Oncol. 17: 500a, 1998.

      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Dose intensity of irinotecan (CPT) combined with weekly cisplatin (CDDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507. International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Sep 2000. Lung Cancer . 29(S1): 38, 2000.

      JCOG9509

      K Kubota, R Itoh, T Kodama, et al.: Concurrent Cisplatin/Etoposide (PE) and Twice-Daily Thoracic Radiotherapy (BID TRT) followed By Weekly Dose Intensive Regimen (CODE) with Human Granulocyte-Colony Stimulating Factor (G-CSF) for Limited Stage (LS) Small Cell Lung Cancer (SCLC). 35th Annual Meeting of the American Society of Clinical Oncology. May 1999. Proc Am Soc Clin Oncol. 18: 513a, 1999.

      JCOG9510

      H Kunikane, K Watanabe, H Kunitoh et al.: A Phase II Study of Cisplatin (CDDP) and Irinotecan (CPT-11) as Chemotherapy (CT) and Sequential Accelerated Hyperfractionated Thoracic Radiotherapy (AH-TRT) with Daily Low Dose Carboplatin (CBDCA) in Unresectable Stage-III Non-Small Cell Lung Cancer (NSCLC) (JCOG Study 9510). 35th Annual Meeting of the American Society of Clinical Oncology. May 1999. Proc Am Soc Clin Oncol. 18: 513a, 1999.

      JCOG9511

      K Noda, Y Nishiwaki, M Kawahara, et al.: Randomized Phase III Study of Irinotecan (CPT-11) and Cisplatin in Extensive-Disease Small-Cell Lung Cancer Japan Clinical Oncology Group Study (JCOG9511). 36th Annual Meeting of the American Society of Clinical Oncology. May 2000. Proc Am Soc Clin Oncol. 19: 483a, 2000.

      S Negoro, K Noda, Y Nishiwaki, et al.: A randomized phase III Study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group study (JCOG9511). International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Sep 2000. Lung Cancer. 29(S1): 30, 2000.

      JCOG9512

      M Makino, H Tsukada, A Yokoyam, et al.: Phase I/II trial of Cisplatin (CDDP), Etoposide (ETP), and Irinotecan (CPT-11) for the treatment of advanced non-small-cell lung cancer (NSCLC). Japan Clinical Oncology Group (JCOG) study 9512. International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Sep 2000. Lung Cancer. 29(S1): 23, 2000.

      JCOG9601

      S Tsuchiya, Y Ohe, T Sugiura, et al.: Randomized Phase I Study of Standard-Fractionated (SDF) and Accelerated-Hyperfractionated (AHF) Radiotherapy with Concurrent Cisplatin and Vindesine (PV) for Unresectable Non-Small Cell Lung Cancer (NSCLC): Japan Clinical Oncology Group (JCOG) 9601. 35th Annual Meeting of the American Society of Clinical Oncology. May 1999. Proc Am Soc Clin Oncol. 18: 525a, 1999.

      JCOG9605/9606

      K Kunitoh, T Tamura, H Fukuda, et al.: Dose intensive chemotherapy (Cx) in advanced thymoma: Initial report of Japan Clinical Oncology Group trials (JCOG9605 and 9606). 42th Annual Meeting of the American Society of Clinical Oncology 2006. Proc Am Soc Clin Oncol. 24: 384, 2006.

      JCOG9702

      H Okamoto, K Watanabe, H Kunikane, et al.: Randomized phase III trial of carboplatin (C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702. 41st Annual Meeting of the American Society of Clinical Oncology. May 2005. Proc Am Soc Clin Oncol. 23(16S): 7010, 2005.

      JCOG9706

      N Yamamoto, M Fukuoka, S Negoro, et al.: A Phase II Study of Induction Chemotherapy (IND CT) with CPT-11 and Cisplatin Followed by Thoracic Radiation (TRT) Combined with Weekly CPT-11 in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC). 36th Annual Meeting of the American Society of Clinical Oncology. May 2000. Proc Am Soc Clin Oncol. 19: 499a, 2000.

      N Takifuji, S Negoro, M fukuoka, et al.: A Phase II Study of Induction Chemotherapy (Ind CT) with CPT-11 and cisplatin followed by thoracic radiation (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small-cell lung cancer (NSCLC): A Japan Clinical Oncology Group (JCOG) 9706 Trial. International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Sep 2000. Lung Cancer. 29(S1): 111, 2000.

      M Kawahara, S Hosoe, M Fukuoka, et al.: A phase II study of induction chemotherapy (IND CT) with CPT-11 and cisplatin followed by thoracic radiotherapy (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small cell lung cancer (NSCLC): final results of Japan Clinical Oncology Group (JCOG) protocol 9706. 38th Annual Meeting of the American Society of Clinical Oncology. May 2002. Proc Am Soc Clin Oncol. 21: 316a, 2002.

      S Negoro, M Fukuoka, M Kawahara, et al.: A phase II study of induction chemotherapy (IND CT) with irinotecan (CPT-11) and cisplatin followed by thoracic radiotherapy (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small cell lung cancer (NSCLC): Final results of JCOG9706. UICC International Cancer Congress. Jun 2002.

      JCOG9811

      H Kunitoh, T Tamura, T Shibata, et al.: A randomized trial of intrapericardial (ip) bleomycin (BLM) after drainage for management of malignant pericardial effusion (MPE) in lung cancer patients (pts) : Report of a Japan Clinical Oncology Group trial (JCOG9811). 43rd Annual meeting of the American Society of Clinical Oncology. Jun 2007. Proc Am Soc Clin Oncol. 25: 436s, 2007.

      JCOG9902-DI

      I Ikuo, Y Nishiwaki, K Noda, et al.: Randmized phase II study of Cisplatin (P), Irinotecan (I), and Etoposide (E) combinations administered weekly or enery four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI. 38th Annual Meeting of the American Society of Clinical Oncology. May 2002. Proc Am Soc Clin Oncol. 21: 306a, 2002.

      N Saijo, I Sekine, T Tamura, et al.: Randomized phase II study of cisplatin (P), Irinotecan (I), and etoposide (E), combinations administered weekly of every four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer. Aug 2003. Lung Cancer. 41(S2): S81, 2003.

      JCOG9903-DI

      K Mori, K Kubota, T Tamura, et al.: Cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) followed by three cycles of irinotecan and cisplatin for the treatment of limited-stage small-cell lung cancer (SCLC); updated results: JCOG 9903-DI. 38th Annual Meeting of the American Society of Clinical Oncology. May 2002. Proc Am Soc Clin Oncol. 21: 294a, 2002.

      K Kubota, Y Nishiwaki, T Tamura, et al.: A pilot study of cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) followed by three cycle of irinotecan and cisplatin for the treatment of limited-stage small-cell lung cancer (SCLC): JCOG9903-DI. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer. Aug 2003. Lung Cancer. 41(S2): S24, 2003.

      JCOG0104

      K Takeda, S Negoro, T Tamura, et al.: Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104). 40th Annual Meeting of the American Society of Clinical Oncology. June 2004. Proc Am Soc Clin Oncol. 23: 622, 2004.

      JCOG0207

      H Tsukada, A Yokoyama, Y Nishiwaki, et al.: Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207. 43rd Annual meeting of the American Society of Clinical Oncology. Jun 2007. Proc Am Soc Clin Oncol. 25: 416s, 2007.

   2. グループ代表者管理の治療研究

      なし

   3. 附随研究等
      • P Lara, M Redman, H Lenz, et al.: Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG9511 and SWOG0124. 43rd Annual meeting of the American Society of Clinical Oncology. Jun 2007. Proc Am Soc Clin Oncol. 15: 390s, 2007.
   4. 総説・解説

      なし